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Abstract
Members of the EGFR/ErbB family of tyrosine kinases are found to be highly expressed and deregulated in many cancers,
including head and neck squamous cell carcinoma (HNSCC). The ErbB family, including EGFR, has been demonstrated to
play key roles in metastasis, tumorigenesis, cell proliferation, and drug resistance. Recently, these characteristics have been
linked to a small subpopulation of cells classified as cancer stem cells (CSCs) which are believed to be responsible for tumor
initiation and maintenance. In this study, we investigated the possible role of EGFR as a regulator of ‘‘stemness’’ in HNSCC
cells. Activation of EGFR by the addition of EGF ligand or ectopic expression of EGFR in two established HNSCC cell lines
(UMSCC-22B and HN-1) resulted in the induction of CD44, BMI-1, Oct-4, NANOG, CXCR4, and SDF-1. Activation of EGFR also
resulted in increased tumorsphere formation, a characteristic ability of cancer stem cells. Conversely, treatment with the
EGFR kinase inhibitor, Gefinitib (Iressa), resulted in decreased expression of the aforementioned genes, and loss of
tumorsphere-forming ability. Similar trends were observed in a 99.9% CD44 positive stem cell culture derived from a fresh
HNSCC tumor, confirming our findings for the cell lines. Additionally, we found that these putative cancer stem cells, when
treated with Gefitinib, possessed a lower capacity to invade and became more sensitive to cisplatin-induced death in vitro.
These results suggest that EGFR plays critical roles in the survival, maintenance, and function of cancer stem cells. Drugs that
target EGFR, perhaps administered in combination with conventional chemotherapy, might be an effective treatment for
HNSCC.
Citation: Abhold EL, Kiang A, Rahimy E, Kuo SZ, Wang-Rodriguez J, et al. (2012) EGFR Kinase Promotes Acquisition of Stem Cell-Like Properties: A Potential
Therapeutic Target in Head and Neck Squamous Cell Carcinoma Stem Cells. PLoS ONE 7(2): e32459. doi:10.1371/journal.pone.0032459
Editor: Wafik S. El-Deiry, Penn State Hershey Cancer Institute, United States of America
Received June 24, 2011; Accepted January 30, 2012; Published February 27, 2012
Copyright:  2012 Abhold et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors’ work was funded by AAOHNSF grant (AAOHNSF.org). The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: wongkeko@ucsd.edu
. These authors contributed equally to this work.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is the 6
th
leading cancer in the world and in many developing countries is
the second most common cancer. In the United States, 30,000–
40,000 cases of head and neck cancer are diagnosed annually.
Despite advances in the field of cancer in general, survival rates
have not improved significantly in more than 30 years [1].
Although the molecular biology of HNSCC is poorly understood,
it is clear that deregulation of several kinases is implicated in the
pathogenesis of this disease. Most prominent among these kinases
is epidermal growth factor receptor (EGFR), a receptor tyrosine
kinase which is overexpressed in a variety of solid tumors,
including the majority of HNSCC, and whose expression is
correlated with a poor clinical outc‘ome [2,3]. Signaling through
EGFR has been implicated in various processes that contribute to
cancer initiation and progression, including cell proliferation, drug
resistance, tumorigenicity, invasion, and metastasis [4,5,6,7].
These same properties have been attributed to cancer stem cells
(CSC), a rare subpopulation of self-renewing cancer cells with the
ability to proliferate extensively and recapitulate tumors [8].
Cancer stem cells have been identified in leukemia as well as in
several solid tumors. In HNSCC, Prince et al demonstrated that
the cell surface marker CD44 could be used to sort and isolate
putative cancer stem cells [9]. These CD44+ lineage negative (Lin-
) cells had a primitive cellular morphology and co-stained with the
basal cell marker Cytokeratin5/14, whereas the CD442 cells
resembled squamous epithelium and expressed the differentiation
marker involucrin. They showed that tumors arising from CD44+
cells reproduced the original tumor heterogeneity and could be
serially passaged, suggesting that CD44+ cells were stem cells, as
they had the properties of differentiation and self-renewal.
Cancer stem cells are thought to arise from progenitor cells
that have acquired stem cell properties through aberrant
behavior of key regulatory genes, proto-oncogenes and tumor
suppressors. Proto-oncogenes, including those that play a key
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thought to promote regenerative capacity by promoting stem cell
function. Conversely, tumor suppressors inhibit regenerative
capacity by promoting cell death or senescence in stem cells, but
also protect against cancer [10]. Members of the EGFR/ErbB
family of receptor tyrosine kinases are proto-oncogenes and are
highly expressed in many cancers of epithelial origin including
HNSCC. EGFR has several known growth factor ligands
including epidermal growth factor (EGF), and TGFa,w h i c h
upon binding to the extracellular domain of EGFR causes the
activation of a number of downstream effectors involved in the
ras/raf-1/mitogen-activated protein kinase, the phosphatidyli-
nositol-3-kinase, and the phospholipase C pathways [11,12].
Activation of these genes results in the expression of other
proteins responsible for cell growth coordination. Overexpres-
sion of EGFR is observed in 42% to 80% of HNSCCs studied
[13]. EGFRvIII, a constitutively active mutant form of EGFR, is
c o m m o ni nH N S C Ca sw e l la si no t h e rc a n c e r sk n o w nt ob e
highly aggressive. Grandis et al demonstrated that EGFR
overexpression provided independent prognostic value for both
local control and survival in 91 head and neck squamous
carcinoma patients treated with surgical resection +/2 postop-
erative radiotherapy [14]. EGFR overexpression was also
associated with both an increased risk of local relapse and an
adverse overall survival, independent of tumor stage.
Due to the link between EGFR and poor prognosis, we
speculated that EGFR may also regulate stem cell characteristics
in HNSCC, chiefly the ability to maintain self-renewal despite
constant proliferation. If this hypothesis were correct, then
constitutive activation of EGFR in normal stem cells or progenitor
cells could ostensibly lead to cancer. A recent clinical study
demonstrated a link between EGFR and ErbB2 inhibition and
reduced CD44
+/CD24
low expression, the cancer stem cell marker
in breast cancer [15,16]. This observation has subsequently been
partially confirmed at the basic science level as ErbB2 has been
demonstrated to regulate the mammary/stem progenitor cell
population [17]. Here, we hypothesized that aberrant activation of
EGFR is one of the key steps that has resulted in the pathogenesis
of HNSCC cancer stem cells. In its behavior as an oncogene,
EGFR can promote acquisition of cancer stem cell-like properties
in HNSCC cancer cells and may determine the fate of progenitor
cells, thus making it an attractive therapeutic target.
Materials and Methods
Ethics statement
Cultures used in this study (JLO-1) were derived in accordance
with the ethics board of Hospital Donostia, San Sebastian, Spain.
Per the hospital’s ethics board, consents are waived when tissue is
obtained anonymously and de-identified. All data analysis
associated with this culture was performed anonymously. Hospital
Donostia, San Sebastian approved this procurement of tissue
including the waiver of consent.
Cell lines and Cell Culture
The HNSCC cell lines used were UMSCC22B, a gift from Dr.
Tom Carey, University of Michigan and HN-1, a gift from Dr. J.S.
Gutkind, National Institute for Dental and Craniofacial Research.
HN-1 was derived from a tongue squamous carcinoma [18], while
22B was derived from a metastatic cervical lymph node of a
patient with hypopharygeal cancer [19]. The cells were cultured in
DMEM supplemented with 10% fetal calf serum, 2% penicillin/
streptomycin, and 2% L-glutamate (GIBCO) and maintained at
37uC in a humidified 5% CO2/95% air atmosphere. JLO-1 is a
putative cancer stem cell culture derived from a fresh laryngeal
tumor, which was obtained from an anonymous patient
undergoing surgical resection at Hospital Donostia (San Sebastian,
Spain) in accordance with their ethics board. Following isolation
by both flow cytometry (CD44+) and selective colony formation on
laminin-coated plates, putative cancer stem cell cultures were
maintained in keratinocyte serum-free media (Invitrogen, Carls-
bad, CA) supplemented with growth factors (EGF and FGF), L-
glutamine (10 mg/mL, Invitrogen, Carlsbad, CA), and gentamy-
cin (Invitrogen, Carlsbad, CA). Cells were grown at 37uCa t5 %
O2 and 10% CO2. EGF ligand (R&D Systems) and the EGFR-
specific tyrosine kinase inhibitor Gefitinib (ZD1839) were dissolved
in DMSO at 10 mMol/L, stored at 220C,and diluted with
DMEM before use.
Quantitative RT-PCR
Cells were harvested two days after being passaged at about 70–
80% confluence. Total cell lysate was collected and RNA was
extracted using an RNeasy kit (Qiagen). cDNA was synthesized
using Superscript III Reverse Transcriptase (Invitrogen, Carlsbad,
CA) as per the manufacturer’s instructions. Real-time PCR
reaction mixes were prepared using Power SYBR Green (Applied
Biosystems, Foster City, CA), and run on the 7300 Real-time PCR
System (Applied Biosystems) using the following program: 95uC
for 10 min, 95uC for 30 s, and 60uC for 1 min, for 40 cycles.
Results were analyzed using the DDCt method. Experiments were
done in technical triplicates and were repeated at least twice
independently. GAPDH gene expression was measured as
endogenous control. Primers were custom ordered (Eurofins
MWG Operon, Huntsville, AL) using the following sequences:
SDF-1 (FOR CTGCCTCAGCGACGGGAAGC – REV TCG-
AGTGGGTCTAGCGGAAAGT), CXCR-4 (FOR TGTGAC-
CGCTTCTACCCCAATGAC – REV GGACAGGATGACAA-
TACCAGGCAG), and beta-actin (FOR CGCTGGATTTTCA-
AAACAGT – REV CTGAGGAGCAGCTTCAGTCC). Oct-3/
4 forward 59- GCAAAGCAGAAACCCTCGTGC-39 reverse 59-
ACCACACTCGGACCACATCCT-39. Nanog forward 59- GA-
TTTGTGGGCCTGAAGAAA-39 reverse 59- TTGGGACTGG-
TGGAAGAATC-39. CD44 forward 59- ACACCACGGGCTTT-
TGACCAC-39 reverse 59- AGGAGTTGCCTGGATTGTGCT-
TG-39. BMI-1 forward 59- TCCACAAAGCACACACATCA-39
reverse 59- CTTTCATTGTCTTTTCCGCC-39.
Western Blotting
Cell lines were lysed in detergent containing 1%
NP40,150 mmol/L NaCl, 1 mmol/L EDTA, 0.1 mmol/L phe-
nylmethylsulfonyl fluoride,1 Ag/mL leupeptin,and 1 Ag/mL
aprotinin, and protein levels were determined using the Bradford
protein assay method (Bio-Rad Laboratories). Thirty micrograms
of total protein was separated on 10% SDS-PAGE gels and
transferred to nitrocellulose membranes. Membranes were
blocked with 5% BSA in TBS with Tween-20 solution for 1 hour
at room temperature and incubated with primary antibodies
(1:1000) in 5% BSA in TBS-T overnight at 4uC. After several
washes in TBST, membranes were incubated for 1 h at room
temperature with the appropriate secondary antibody (1:10,000).
The membranes were again washed several times and the protein-
antibody complexes were detected using Luminol Reagent
(Thermo Scientific). Antibodies used for blotting included anti-
BMI (ABCam), anti-CD44 (ABCam), Anti-Oct4 (ABCam), Anti-
Nanog (Cell Signaling), Anti-SDF1 (ABCam), Anti-CXCR4
(ABCam), Anti-EGFR (SantaCruz Biotechnology), and Anti-B-
Actin (Cell Signaling).
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Cells were seeded in a 24-well low adhesion plate (Corning Inc,
Lowell, MA) at a density of 1000 cells/well and an initial volume
of 500 ul as described by Dontu et al [20]. Spheres were grown in
DMEM F12 medium (Gibco) supplemented with Vitamin B27,
20 ng/ml FGF, and 4 ug/ml of heparin. Samples were
subsequently treated with 0, 10, 50, or 100 ng/ml of epidermal
growth factor (R&D Biosystems) or 2 mM Gefitinib. EGF and
FGF were replenished every three days. Aside from the addition
of heparin, cells were agitated daily to minimize clumping.
Spheres were counted and photographed after 10 days of
continuous ligand or inhibitor exposure. Spheres were monitored
under the microscope daily to ensure that they were derived from
single cells and that they did not become confluent during the
experiment.
Immunofluorescence
To determine the effect of gefitinib on the expression of CD44
in our putative cancer stem cell culture, JLO-1, cells were
incubated with 2 mM gefitinib for 24 hours. The cells were fixed
with 4% paraformaldehyde and blocked in goat serum at room
temperature prior to incubation with the monoclonal CD44
antibody (R&D Systems, Minneapolis, Minnesota). Cells tagged
with the CD44 antibody were then incubated with goat anti-rabbit
fluorescein isothiocyanate (FITC)
2conjugated secondary antibody
(Chemicon). Cells were counterstained with 4,6-diamidino-2-
phenylindole (DAPI). Images were taken at the original magnifi-
cation of 406. Fluorescent images were obtained using a Leica
inverted fluorescence microscope (model DMIRE2; Leica Micro-
systems, Deerfield, Illinois). The computer software Simple PCI
(Compix Inc, Sewickley, Pennsylvania) was used for image
capture.
Invasion Assay
Invasion of JLO-1 cells was measured using a Matrigel invasion
assay (Becton Dickinson, Bedford, MA). Transwell inserts of 8 mm
pore size were coated with a final concentration of 1 mg/mL of
Matrigel in cold serum-free DMEM. Cells were trypsinized, and
1610
5 cells were added in triplicate wells. The lower chamber of
the transwell was filled with 750 ml of culture media containing
0.5% serum as a chemoattractant, along with the treatment of
either 20 ng/ml EGF or 20 mM Gefitinib and allowed to incubate
at 37uC for 24 hours. Invading cells on the lower surface that
passed through the filter were fixed and stained using crystal violet
in gluteraldehyde and photographed.
Flow Cytometry Analysis
JLO-1 cells were trypsinized and incubated with either the
monoclonal CD44 antibody conjugated to the fluorescent dye
phycoerythrin (R & D Systems, Minneapolis, Minnesota) or the
monoclonal EGFR antibody conjugated to the fluorescent dye
allophycocyanin R & D Systems, Minneapolis, Minnesota).
Samples were analyzed by flow cytometry and gated in
comparison to an unlabeled control.
MTS Assay
JLO-1 cells were plated into a 96 well flat-bottom tissue culture
plate (Falcon) at a density of 5,000 cells per well. After a 24 hour
plating period, half of the wells were treated with 2 mM Gefitinib
and incubated for 48 hours. The control and Gefitinib-treated
cells were subsequently exposed to one of several doses of cisplatin
ranging from 0–20 mM. After a 24 hour incubation period, the
cells were analyzed for chemoresistance using an MTS prolifer-
ation assay (Promega) in accordance with the manufacturer’s
protocol. All assays were performed in triplicate.
Results
EGFR activation regulates the expression of cancer stem
cell markers in HNSCC cell lines
We first sought to determine whether EGFR might regulate the
expression of a set of well-established cancer stem cell markers.
CD44 and BMI-1 have been shown to indicate stem cell
phenotype in HNSCC [9]. Oct-4 and Nanog are pluripotency
and self-renewal markers in embryonic stem cells, but are also
found to be overexpressed in many cancers. The CXCR4/SDF-1
axis is known to be responsible for invasion and metastasis in
pancreatic cancer, and is a hematopoietic stem cell marker. 22B
and HN-1 cells were serum starved overnight, treated with 20 ng/
ml EGF ligand for 24 hours, and then harvested for total RNA or
protein. Quantitative polymerase chain reaction was then used to
compare expression levels between control and EGF treated cells
(Figure 1a). EGF treated cells experienced 1.5 to 4-fold increases in
expression of Bmi-1, CD44, Oct-4, Nanog, CXCR4 and SDF-1
mRNA. In contrast, cells treated with 2 mM Gefitinib, a small
molecule inhibitor of EGFR, experienced 2 to 5 fold decreases in
the same set of genes (Figure 1b). Using western blots, these results
were verified at the protein level for the HNSCC stem cell markers
BMI-1 and CD44 (Figure 1c, d). Relative levels of protein were
quantified by performing densitometric analysis on each band and
comparing the ratio of CD44 or BMI-1 to Actin between samples,
with control samples set arbitrarily to 1. These results demonstrate
that EGFR signaling might regulate cancer stem cell properties, as
it induces the expression of genes responsible for self-renewal,
pluripotency, and metastasis.
Overexpression of EGFR induces the expression of cancer
stem cell genes in HNSCC cell lines
EGFR is overexpressed in 90% of head and neck cancers [7].
To determine whether EGF is acting through EGFR or a
secondary target, exogenous EGFR was overexpressed in both
HNSCC cell lines in the presence of serum and exposed to either 0
or 20 ng/ml EGF ligand. EGFR overexpression alone resulted in
a significant increase in all six CSC genes (Figure 2a). The addition
of EGF ligand to EGFR-overexpressing cells had various effects on
the six CSC genes, either increasing expression (CD44, Oct-4, and
Sdf-1), having no appreciable effect (BMI1, CXCR4), or causing a
decrease in expression (Nanog). These results suggest that BMI
and CXCR4 may already have reached a maximum expression
level. Furthermore, these results suggest that EGF ligand may also
activate an opposing pathway controlling Nanog expression,
leading to a slightly diminished increase in Nanog expression.
Interestingly, no significant change in CD44, BMI-1, Nanog, and
Oct-4 was observed at the mRNA level upon ectopic overexpres-
sion of EGFR in both UMSCC-22B and HN-1, suggesting
involvement of a post-transcriptional mechanism (Figure 2b, c).
Taken together, these results demonstrate that EGFR activity is
responsible, via post-translational regulation, for the shown
increase in the CSC gene expression.
EGFR kinase regulates tumorsphere formation in HNSCC
cell lines and putative HNSCC stem cells
To further demonstrate the role of EGFR activity in regulating
CSC properties, we determined whether EGFR could regulate
tumorsphere formation. Spheres have been shown to be enriched
for cancer stem cells, and are used as a measure of stemness in
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described in Dontu et al, for cells treated with either 0, 10, 50,
or 100 ng/ml of EGF ligand or 2 mM Gefitinib (Figure 3a–d).
22B, HN-1, and a putative cancer stem cell culture (JLO-1) were
seeded in a 24-well low adhesion plate at 1000 cells per well. The
cells were treated for two weeks after which the spheres were
counted and photographed. EGF ligand enhanced self-renewal
capacity in both established HNSCC cell lines and our putative
cancer stem cell line, as indicated by the dose dependent increase
in sphere formation and sphere size. Meanwhile, Gefitinib
exposure led to a significant decrease in sphere-formation ability.
In order to ensure that the observed reduction in sphere formation
was due primarily to inhibition of stem cell phenotype rather than
decrease in cell viability, a MTS cell viability assay was performed
to ensure that no significant reduction in cell viability occurred
over a period of 7 days at the relevant doses of Gefitinib (Figure 3e).
EGFR inhibition decreases CD44 expression in putative
HNSCC stem cell culture
We measured by flow cytometry the proportion of CD44 and
EGFR-expressing JLO-1 cells. 88.9% showed high expression of
EGFR (Figure 4a) and 99.9% had high expression of CD44
(Figure 4b). In order to further demonstrate the connection
between EGFR activity and acquisition of stem cell properties, we
looked at the effect of EGFR inhibition on expression of CD44
protein. Immunofluorescence analysis revealed that cell surface
expression of CD44 was lowered dramatically in response to
treatment with Gefitinib (Figure 4c). Flow cytometric analysis was
also performed to verify the reduction in CD44 expression
(Figure 4d). Flow analysis revealed a 0.5-fold reduction in mean
PE fluorescence accompanied by an approximate 4.5-fold
expansion (2.1% to 9.0%) of the CD44 negative population.
Given that CD44 is the main stem cell marker for HNSCC, these
results suggest that EGFR activation may be crucial for
maintaining a cancer stem cell phenotype.
EGFR inhibition sensitizes cells to cisplatin and blocks
cellular invasion in a putative HNSCC stem cell culture
We performed an MTS assay to test the viability of Iressa-
treated JLO-1 cells in the presence of cisplatin (Figure 5a). Our
results showed that treatment with 2 mM of Iressa sensitized the
cells to cisplatin. This suggests that Iressa may be effective in
Figure 1. EGFR signaling regulates the expression of stem cell and metastatic markers in the HNSCC cell lines 22B and HN-1. (A)
Treament with 20 ng/ml EGF induced the expression of CD44, BMI-1, Oct-4, Nanog, CXCR4 and SDF-1alpha. (B) Treatment with 2 mM of Gefitinib
lowered the expression of CD44, BMI1, Oct-4, Nanog, CXCR4 and SDF-1alpha. Error bars represent SD. * indicates p,.05, *** indicates p,.01,
*** indicates p,.001 (C) Effect of 20 ng/ml EGF or 2 mM Gefitinib on the expression of BMI-1 and CD44 protein in 22B cells. (D) Effect of 20 ng/ml EGF
or 2 mM Gefitinib on the expression of BMI-1 and CD44 protein in HN-1 cells.
doi:10.1371/journal.pone.0032459.g001
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matrigel invasion assays were performed to test the role of EGFR
signaling in regulating cellular invasion (Figure 5b, c). Results
showed that treatment with 20 ng/ml of EGF ligand increased
invasion by 1.6-fold, while inhibition using 2 mM of Iressa lowered
invasion by greater than 2-fold. These results are clinically relevant
as EGFR expression has been positively correlated with poor
clinical outcome. In addition, it shows that Gefitinib may be an
effective agent for use in combination with conventional
chemotherapy by promoting drug sensitization and inhibiting
invasion.
Discussion
Although it is known that EGFR facilitates cancer progression
by inducing cell growth and proliferation, these effects alone may
not be enough to overcome the natural barriers of senescence and
terminal differentiation. It is likely that secondary mechanisms, in
addition to mitotic stimulation, exist to circumvent such barriers
and allow cancer cells to thrive indefinitely. Here we have shown
that EGFR possibly fulfills that role, as EGFR activation promoted
the acquisition and maintenance of various cancer stem cell
characteristics including the expression of self-renewal markers
and capacity to form tumorspheres. In addition, we have found
that EGFR promotes invasion and chemoresistance in a putative
cancer stem cell culture, suggesting that EGFR also regulates
malignant behavior in cancer stem cells. These observations
suggest that EGFR deregulation might be an important step in the
conversion of adult stem cells or progenitor cells into malignant
cancer stem cells.
One of the prevailing models is that cancer stem cells arise from
progenitor cells that have obtained the ability to self-renew. Under
normal development, EGFR is used to promote proliferation and
self-renewal of adult stem cells, and becomes tightly regulated or
inactivated as they differentiate into progenitor cells. In cancer, it
is possible that mutations would cause EGFR to remain
constitutively active even in differentiated cells, resulting in
maintenance or acquisition of self-renewal properties. The most
common mutant form, EGFRvIII, is a hallmark of highly
aggressive cancers and is present in 42% of HNSCC tumors
[21]. It was shown that HNSCC cell lines transfected with
EGFRvIII show increased proliferation and decreased sensitivity
to cisplatin-induced apoptosis. Furthermore, ectopically expressed
EGFRvIII was found to inhibit differentiation and promote
migration in both neural stem cells and neural progenitors [22,23].
Our findings, taken together with these observations, suggest the
possibility that aberrant activation of EGFR in cancer can lead to
acquisition and maintenance of stem cell properties. Future work is
needed to elucidate the downstream pathways that regulate
EGFR-induced stemness, although it is likely that these effects are
at least partly mediated by the PI3K/Akt pathway, which in turn
regulates a variety of stem cell functions including proliferation,
self renewal, invasion and drug resistance.
We observed that both activation and overexpression of EGFR
resulted in increased expression of stem cell markers. Transient
overexpression of EGFR in our cell lines increased the protein
Figure 2. EGFR overexpression induces protein expression of cancer stem cell markers in HNSCC cell lines. (A) EGFR overexpression
induces higher protein levels of stem cell and metastatic markers in the HNSCC cell lines 22B and HN-1. EGFR was transiently overexpressed in the cell
lines 22B and HN-1, and protein levels were measured 48 hours later by western blotting. (B) No significant change in mRNA levels was observed in
22B cells upon EGFR overexpression, suggesting a potential post-transcriptional mechanism. (C) No significant change in mRNA levels was observed
in HN-1 cells upon EGFR overexpression, suggesting a potential post-transcriptional mechanism.
doi:10.1371/journal.pone.0032459.g002
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Addition of EGF simultaneously slightly lowered the expression of
Nanog compared to overexpression of EGFR alone, indicating a
possible negative feedback loop. A possibility is that the addition of
EGF increases the expression of Oct-4 past a certain threshold, at
which it begins to repress the Nanog promoter. This relationship
has been well-demonstrated in embryonic stem cells [24].
Interestingly, EGFR overexpression resulted in increased expres-
sion of stem cell markers at the protein level but did not generate
significant change in expression at the mRNA level, suggesting a
post-transcriptional regulatory mechanism.
Recent studies suggest that specific targeting of cancer stem cells
improves disease outcomes in mice [25,26]. Our results suggest
EGFR inhibition might be an effective method to target the cancer
stem cell population in HNSCC. Thus, treatments that combine
EGFR inhibitors with conventional chemotherapy will target both
Figure 3. EGFR regulates tumorsphere formation in HNSCC cell lines and in a putative cancer stem cell culture. (A) EGF increased the
rate of sphere formation in a dose-dependent fashion in 22B and HN-1 cells, while addition of 2 mM gefitinib significantly decreased sphere
formation. (B) EGF increased the rate of sphere formation in JLO-1, a putative cancer stem cell culture. Error bars represent SEM. Gefitinib (0 to 2 mM)
reduced sphere formation in a dose-dependent fashion in JLO-1. (C) Brightfield micrographs showing sphere formation in 22B and HN-1 after
treatment with Gefitinib or EGF. (D) Brightfield micrographs showing sphere formation in JLO-1 after treatment with Gefitinib or EGF. (E) MTS cell
viability assay demonstrating negligible effect of Gefitinib (Iressa) on cell viability at doses of up to 2 mM, showing that the observed decrease in
sphere formation is not due to lower cell viability.
doi:10.1371/journal.pone.0032459.g003
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PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e32459Figure 4. Gefitinib inhibits CD44 expression in putative cancer stem cells. (A) Flow cytometric analysis showing a high proportion (88.9%)
of EGFR+ JLO-1 cells. (B) Flow cytometric analysis showing a high proportion (99.9%) of CD44+ JLO-1 cells. (C) Immunofluoresence microscopy
showing the effect of 2 mM gefitinib on cell-surface CD44 expression in JLO-1. CD44 fluorescence (Red) is markedly reduced in the bottom two
panels, suggesting that EGFR activity is essential for CD44 expression. (D) Flow cytometric analysis quantifying the change in CD44 expression and
size of CD44-negative population upon treatment with Gefitinib.
doi:10.1371/journal.pone.0032459.g004
Figure 5. Gefitinib enhances cisplatin-induced death and lowers invasive capacity in putative cancer stem cells. (A) MTS assay
comparing the survival curves of control JLO-1 to 2 mM gefitinib-treated JLO-1 when subjected to increasing doses of cisplatin. Gefitinib-treated JLO-
1 lost their viability at noticeably lower doses in comparison to control cells. (B) Matrigel invasion assay comparing relative number of cells invaded
between control, EGF-treated, and Gefitinib-treated JLO-1. (C) Representative photographs of the bottom surfaces of the invasion chambers, showing
clear differences in the number of invaded cells between the three samples.
doi:10.1371/journal.pone.0032459.g005
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greatly reducing the possibility of relapse and secondary tumors.
Additionally, our findings demonstrate that the role of EGFR in
HNSCC extends beyond its traditional function as a promoter of
cell growth, as it could regulate the key properties of cancer stem
cells that are essential for cancer initiation and progression.
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